Advertisement

Comment on: “Serum bile acids in cystic fibrosis patients – glycodeoxycholic acid as a potential marker of liver disease”

Published:August 24, 2022DOI:https://doi.org/10.1016/j.dld.2022.08.014
      We have avidly read the recent study, “Serum bile acids in cystic fibrosis patients – glycodeoxycholic acid as a potential marker of liver disease” by Sawomira Drzymaa-czy et al. [
      • Drzymała-Czyż S.
      • Dziedzic K.
      • Szwengiel A.
      • Krzyżanowska-Jankowska P.
      • Nowak J.K.
      • Nowicka A.
      • Aringazina R.
      • Drzymała S.
      • Kashirskaya N.
      • Walkowiak J
      Serum bile acids in cystic fibrosis patients - glycodeoxycholic acid as a potential marker of liver disease.
      ] and we commend the authors for their diligent work. Numerous studies demonstrate that cystic fibrosis and its related liver disease can induce changes in bile acid metabolism. We agree with the study's summary that a CF-related specific bile acid profile is associated with liver disease and glycodeoxycholic acid distinguishes patients with non-cirrhotic liver involvement from those without detectable liver disease. Therefore, glycodeoxycholic acid has potential to be a valid biomarker of non-cirrhotic liver disease development in CF. However, we believe it is necessary to include other significant aspects that would improve the quality of this article and add to our understanding of chronic hepatic diseases.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Drzymała-Czyż S.
        • Dziedzic K.
        • Szwengiel A.
        • Krzyżanowska-Jankowska P.
        • Nowak J.K.
        • Nowicka A.
        • Aringazina R.
        • Drzymała S.
        • Kashirskaya N.
        • Walkowiak J
        Serum bile acids in cystic fibrosis patients - glycodeoxycholic acid as a potential marker of liver disease.
        Dig Liver Dis. 2022; 54 (Epub 2021 Jul 22. PMID:34305015): 111https://doi.org/10.1016/j.dld.2021.06.034
        • Colombo C.
        • Alicandro G.
        • Oliver M.
        • Lewindon P.J.
        • Ramm G.A.
        • Ooi C.Y.
        • Alghisi F.
        • Kashirskaya N.
        • Kondratyeva E.
        • Corti F.
        • Padoan R.
        • Asherova I.
        • Evans H.
        • de Monestrol I.
        • Strandvik B.
        • Lindblad A.
        • CF UDCA study group
        Ursodeoxycholic acid and liver disease associated with cystic fibrosis: a multicenter cohort study.
        J Cyst Fibros. 2022; 21 (Epub 2021 Apr 2. PMID:33814323): 220-226https://doi.org/10.1016/j.jcf.2021.03.014
        • Caparrós-Martín J.A.
        • Flynn S.
        • Reen F.J.
        • Woods D.F.
        • Agudelo-Romero P.
        • Ranganathan S.C.
        • Stick S.M.
        • O'Gara F
        The Detection of Bile Acids in the Lungs of Paediatric Cystic Fibrosis Patients Is Associated with Altered Inflammatory Patterns.
        Diagnostics (Basel). 2020 May 6; 10 (PMID:32384684 PMCID: PMC7277992): 282https://doi.org/10.3390/diagnostics10050282
        • van de Peppel I.P.
        • Doktorova M.
        • Berkers G.
        • de Jonge H.R.
        • Houwen R.H.J.
        • Verkade H.J.
        • Jonker J.W.
        • Bodewes F.A.J.A
        IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.
        J Cyst Fibros. 2019; 18 (Epub 2018 Sep 29. PMID:30279125): 286-293https://doi.org/10.1016/j.jcf.2018.09.001
        • Flynn S.
        • Reen F.J.
        • Caparrós-Martín J.A.
        • Woods D.F.
        • Peplies J.
        • Ranganathan S.C.
        • Stick S.M.
        • O'Gara F
        Bile Acid Signal Molecules Associate Temporally with Respiratory Inflammation and Microbiome Signatures in Clinically Stable Cystic Fibrosis Patients.
        Microorganisms. 2020; 8 (PMID:33172004 PMCID: PMC7694639): 1741https://doi.org/10.3390/microorganisms8111741

      Linked Article